

This policy applies to the following:

	Standard Opt-in		PDPD		Marketplace		Medical Benefit	✓	Medicare Part B	Reference # 4659-D
	Standard Opt-out		ACSF		MMT		Medical Benefit: Biosimilars First		Medicare Part B: Biosimilars First	
	VF		Balanced		Medical Benefit: Managed Medicaid		Medical Benefit: Add-on		Medicare Part B: Add-on	

## EXCEPTIONS CRITERIA ASTHMA

### PREFERRED PRODUCTS: FASENRA, NUCALA AND XOLAIR

#### POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

#### I. PLAN DESIGN SUMMARY

This program applies to the asthma products specified in this policy. Coverage for targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with the targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

**Table. Asthma products**

	Product(s)
<b>Preferred*</b>	<ul style="list-style-type: none"> <li>• <b>Fasenra</b> (benralizumab)</li> <li>• <b>Nucala</b> (mepolizumab)</li> <li>• <b>Xolair</b> (omalizumab)</li> </ul>
<b>Targeted</b>	<ul style="list-style-type: none"> <li>• <b>Cinqair</b> (reslizumab)</li> </ul>

\*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

#### II. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred products.

Coverage for the targeted product is provided when either of the following criteria is met:

- A. Member has received treatment with the targeted product in the past 365 days.
- B. Member has a documented inadequate response or intolerable adverse event with all of the preferred products.

#### REFERENCES

1. Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2020.

Specialty Exceptions Asthma MED B 4659-D P2022.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

This policy applies to the following:

	Standard Opt-in		PDPD		Marketplace		Medical Benefit	✓	Medicare Part B
	Standard Opt-out		ACSF		MMT		Medical Benefit: Biosimilars First		Medicare Part B: Biosimilars First
	VF		Balanced		Medical Benefit: Managed Medicaid		Medical Benefit: Add-on		Medicare Part B: Add-on

Reference #
4659-D

2. Cinqair [package insert]. West Chester, PA: Teva Respiratory, LLC; February 2020.
3. Fasentra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2021.
4. Xolair [package insert]. South San Francisco, CA: Genentech, Inc.; December 2020.